Bend, OR, USA, November 29, 2021 — The newly formed company, Phoenix-Micron, Inc., announced today it has completed the spin-out of the Phoenix MICRON® imaging platform from Phoenix Technology Group. This move is designed to increase focus and innovation in products designed to serve the eye and eye-brain research community. The new company, Phoenix-Micron, Inc.
29.07
2021
Subretinal injection damage has implication for experimental control and treatment in rat model of retinopathy of prematurity
In their 2017 article, “Effect of subretinal injection on retinal structure and function in a rat oxygen-induced retinopathy model,” Becker et al used the Phoenix MICRON® IV fundus camera, Phoenix MICRON® OCT2 and corresponding layer analysis software Insight 2D, and the Phoenix MICRON® focal ERG to find that subretinal injection of saline or even introduction
25.03
2021
Therapeutic target for retinal degeneration studied with the Phoenix MICRON® retinal structure and function tools
In their article, “Effect of MMP-9 gene knockout on retinal vascular form and function,” George et al study the effect of knocking out a matrix protein in a mouse model of retinitis pigmentosa using the Phoenix MICRON® platform including OCT, and Ganzfeld ERG. The combination of the Phoenix MICRON® fundus images, OCT revealing the layers,
29.09
2020
RPE mutations lead to retinal hypopigmentation, vasculature changes, and decreased function
In their paper, “The microphthalmia-associated transcription factor (Mitf) gene and its role in regulating eye function,” García-Llorca et al use the Phoenix MICRON® IV to examine the outer eye appearance, retinal pigmentation, and retinal vasculature through fluorescein angiography to study several different mouse mutants. Combined with electroretinography and histology, the fundus images tell a story
21.07
2020
Caspase-9 inhibiting eyedrops rescue physiological and functional retinal vein occlusion damage shown with Phoenix MICRON®, OCT, and focal ERG
In a recent well written, compelling article published in Nature Communications, “Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion,” Avrutsky et al show that caspase-9 inhibition is a promising treatment for retinal vein occlusion. Retinal vein occlusion models hypoxic-ischemic neurovascular damage and is the second leading cause of blindness in working-age adults.
23.06
2020
Targeting VEGF164 in Müller cells may be useful to treat retinopathy of prematurity
In Nature’s Scientific Reports, Becker et al use the Phoenix MICRON® IV, OCT, and focal ERG to assess the therapeutic value of knocking down a splice variant of VEGF in Müller cells in a model of Retinopathy of Prematurity (ROP). ROP is characterized by delayed vascularization of the retina after disrupted oxygen levels, followed by